← Leaderboards
Dori A Thomas-Karyat
Synthis Therapeutics, Inc.
$3,109,651
Attributed
$3,109,651
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,109,651 · 4
By mechanism
R44$1,999,830 · 1
R43$1,109,821 · 3
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Automobile Driving”
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Scott Topper · Broad Institute, Inc.$30,147,501
- Leonard Freedman · Leidos Biomedical Research, Inc.$15,624,898
- Ganesh M Babulal · Washington University$11,062,209
- Christopher A. Gaiteri · Rush University Medical Center$9,886,289
Research focus
Automobile DrivingMediatingTumorImmunePatient ResponseBiotechnologySignal TransductionToxic EffectCellsAntibody-Drug ConjugatesIn VitroSmall Business Innovation Research GrantIn VivoMalignant NeoplasmsDoseCytokineT-LymphocyteImmune Checkpoint InhibitorCd8-Positive T-LymphocytesAntibodiesCheckpoint TherapyImmunosuppressionCancer PatientResistance
Grant awards (7)
In vivo efficacy, safety and PK/PD analysis of SYN101, a first in class, immune cell targeted TGFb therapy for cancer patients$1,420,853
R44 · FY2025 · CA · contact PI
In vivo efficacy, safety and PK/PD analysis of SYN101, a first in class, immune cell targeted TGFb therapy for cancer patients$578,977
R44 · FY2024 · CA · contact PI
Development of a targeted TGF-b therapeutic that selectively blocks lung fibrosis in idiopathic pulmonary fibrosis (IPF) patients$299,900
R43 · FY2023 · HL · contact PI
Development of a novel checkpoint inhibitor-TGF beta combination therapy to reverse immune suppression and increase survival rates in advanced colorectal cancer patients$210,000
R43 · FY2020 · CA · contact PI
Development of a novel checkpoint inhibitor-TGF beta combination therapy to reverse immune suppression and increase survival rates in advanced colorectal cancer patients$243,905
R43 · FY2019 · CA · contact PI
Development of a novel checkpoint inhibitor-TGF beta combination therapy to reverse immune suppression and increase survival rates in advanced colorectal cancer patients$56,070
R43 · FY2019 · CA · contact PI
Development of a T cell-targeted TGF-b antagonist that reverses immune suppression in melanoma patients$299,946
R43 · FY2018 · CA · contact PI